PharmaShots | Incisive News in 3 Shots

Subscribe Now

Lannett

Lannett Entered into a Patent License Agreement with Ypsomed and HEC for Pen Injector Device in Use of Biosimilar Insulin Glargine and Insulin Aspart

Lannett Entered into a Patent License Agreement with Ypsomed and HEC for Pen Injector Device in Use of Biosimilar Insulin Glargine...

November 7, 2022

Lannett Reports the Completion of Patient Dosing in Pivotal Clinical Trial for Biosimilar Insulin Glargine

Lannett Reports the Completion of Patient Dosing in Pivotal Clinical Trial for Biosimilar Insulin Glargine

August 31, 2022

Lannett Reports Updates of Biosimilar Insulin Glargine

Lannett Reports Updates of Biosimilar Insulin Glargine

June 1, 2022

Insights+ Key Biosimilars Events of March 2022

Insights+ Key Biosimilars Events of March 2022

April 7, 2022

Lannett Reports the First Patient Dosing in the Pivotal Clinical Trial of Biosimilar Insulin Glargine

Lannett Reports the First Patient Dosing in the Pivotal Clinical Trial of Biosimilar Insulin Glargine

March 29, 2022

Lannett Receives the US FDA’s IND Clearance of Biosimilar Insulin Glargine

Lannett Receives the US FDA’s IND Clearance of Biosimilar Insulin Glargine

January 21, 2022

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us